Christopher J Record,Mariola Skorupinska,Matilde Laura,Alexander M Rossor,Davide Pareyson,Chiara Pisciotta,Shawna M E Feely,Thomas E Lloyd,Rita Horvath,Reza Sadjadi,David N Herrmann,Jun Li,David Walk,Sabrina W Yum,Richard A Lewis,John Day,Joshua Burns,Richard S Finkel,Mario A Saporta,Sindhu Ramchandren,Michael D Weiss,Gyula Acsadi,Vera Fridman,Francesco Muntoni,Roy Poh,James M Polke,Stephan Zuchner,Michael E Shy,Steven S Scherer,Mary M Reilly,Lisa Abreu,Kimberly A Anderson,Silvia Baratta,Debbie Berry,Julian Blake,Eleonora Cavalca,Kayla Cornett,Andrea Cortese,Gabrielle Donlevy,Amanda Dragon,Magdalena Dudziec,Katy Eichinger Tim Estilow,Valerie Ferment,Natalie Grant,Tiffany Grider,Emily Hyslop,Tara Jones,Nicole Kressin,Wendy Leon,Stefania Magri,Brett McCray,Manoj Menezes,Evelin Milev,Lindsey Parrott,Pooja Patel,Cláudia Brito Pires,Valeria Prada,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary Shy,Carly Siskind,Janet Sowden,Sydney Stork,Charlotte J Sumner,Franco Taroni,Simone Thomas,Jennifer Twachtman-Bassett,Nidia Villalpando,Dragan Vujovic,Julie Wells,Elizabeth Wood,Riccardo Zuccarino,for the Inherited Neuropathies Consortium - Rare Disease Clinical Research Network

Abstract:Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterised by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1 . Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and 3 benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar's classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G>A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness (change in CMTES (ΔCMTES) = 1.3 ± 2.6, p = 0.00016, SRM = 0.50). Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0-7; 3-year ΔCMTES = 2.3 ± 2.5, p = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.

Insights into phenotypic variability caused by GARS1 pathogenic variants

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

A previously unreported NARS1 variant causes dominant distal hereditary motor neuropathy in a French family

A familial form of Charcot-Marie-Tooth disease (type 2d) caused by a previously unreported variant in GARS1

A Novel Mutation of GARS in a Chinese Family with Distal Hereditary Motor Neuropathy Type V

GARS-related Disease in Infantile Spinal Muscular Atrophy: Implications for Diagnosis and Treatment

A Novel Mutation of the Glycyl-Trna Synthetase (gars) Gene Associated with Charcot-Marie-Tooth Type 2d in A Chinese Family

Mild Late-Onset Sensory Neuropathy Associated with Heterozygous Missense GDAP1 Variants

A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis

Alanyl-tRNA Synthetase 1 Gene Variants in Hereditary Neuropathy: Genotype and Phenotype Overview

Glycyl-tRNA sequestration is a unifying mechanism underlying GARS1-associated peripheral neuropathy

Characterization of a novel heterozygous variant in the histidyl‐tRNA synthetase gene associated with Charcot–Marie–Tooth disease type 2W

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

Phenotype of Patients With Charcot-Marie-Tooth With the p.His123Arg Mutation in GDAP1 in Northern Finland

Clinical characteristics and proteome modifications in two Charcot-Marie-Tooth families with the AARS1 Arg326Trp mutation

Charcot-Marie-Tooth–Linked Mutant GARS Is Toxic to Peripheral Neurons Independent of Wild-Type GARS Levels

Expanding the Clinical Spectrum of DRP2 -Associated Charcot-Marie-Tooth Disease

Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

Genetic and Clinical Features in 24 Chinese Distal Hereditary Motor Neuropathy Families

Comprehensive functional characterization of SGCB coding variants predicts pathogenicity in limb-girdle muscular dystrophy type R4/2E

Infantile‐onset CMT2D/dSMA‐V in a Chinese Family with Parental Germline Mosaicism for a Novel Mutation in the GARS1 Gene